18F-FTC-146 PET/CT in Newly-Diagnosed Osteosarcoma

Trial ID or NCT#

NCT04365660

Status

not recruiting iconNOT RECRUITING

Purpose

The purpose of this research is to evaluate the study drug, 18F FTC-146, as a positron emission tomography (PET) / computed tomography (CT) radiotracer imaging agent to evaluate tumor status in patients newly diagnosed with osteosarcoma ("bone cancer").

Official Title

A Phase 2 Study of 18F FTC 146 PET/CT in Patients With Newly Diagnosed Osteosarcoma

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Patients with biopsy proven osteosarcoma requiring local surgical intervention. - ECOG ≤ 2 - Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
  1. - Chemotherapy in the past 2 months. - Prior history of allergic reaction to 18F FTC 146. - Pregnant or nursing
View All Criteria
Show Less

Investigator(s)

Kristen N Ganjoo
Kristen N Ganjoo
Sarcoma specialist, Medical oncologist
Professor of Medicine (Oncology)

Contact us to find out if this trial is right for you.

Contact

Denise Montes
650-725-4185

View on ClinicalTrials.gov